Artiva Biotherapeutics Logo.jpg
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 29, 2024 16:05 ET | Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Transparency Market Research
Apheresis Market Size to Surge to USD 6.7 Billion by 2034, Driven by Strong Growth Momentum at 7.7% CAGR | Report by Transparency Market Research, Inc.
August 28, 2024 18:30 ET | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Aug. 28, 2024 (GLOBE NEWSWIRE) -- As per the report published by Transparency Market Research, the global apheresis market...
ImmuneSensor_Resize.png
ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301
August 19, 2024 08:00 ET | ImmuneSensor Therapeutics
Novel, oral IMSB301 is a potent cGAS inhibitor designed to block signaling through a central pathway that drives diverse inflammatory and autoimmune diseases Company expects to initiate its Phase 1...
Picture1.png
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 08, 2024 07:00 ET | Autolus Therapeutics plc
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
Alumis.png
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
July 29, 2024 08:00 ET | Alumis Inc.
Alumis announced that patient dosing has commenced in the ONWARD Phase 3 clinical program for ESK-001 for the treatment of psoriasis.
Picture1.png
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
July 26, 2024 07:00 ET | Autolus Therapeutics plc
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
July 18, 2024 19:08 ET | Artiva Biotherapeutics Inc.
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
22157.jpg
Synthetic Immunology Market Report 2024 with Profiles of ADC Therapeutics, BioNTech, Camena Bioscience, CRISPR Therapeutics, Editas Medicine, Sherlock Biosciences, Synlogic Therapeutics & Synthego
July 04, 2024 07:28 ET | Research and Markets
Dublin, July 04, 2024 (GLOBE NEWSWIRE) -- The "Synthetic Immunology Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Synthetic Immunology Market is...
Alumis.png
Alumis Announces Pricing of Initial Public Offering
June 27, 2024 23:57 ET | Alumis Inc.
Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering
Antion Logo - RGB - Web version-01.png
Antion Biosciences announces development of safety-enhanced and off-the-shelf CAR T-cells for autoimmune disease
May 22, 2024 06:55 ET | ANTION BIOSCIENCES SA
Aiming for a best-in-class solution to treat and cure B-cell driven autoimmune diseases